Cargando…
Invalidation of dieckol and 1,2,3,4,6-pentagalloylglucose (PGG) as SARS-CoV-2 main protease inhibitors and the discovery of PGG as a papain-like protease inhibitor
The COVID-19 pandemic spurred a broad interest in antiviral drug discovery. The SARS-CoV-2 main protease (M(pro)) and papain-like protease (PL(pro)) are attractive antiviral drug targets given their vital roles in viral replication and modulation of host immune response. Structurally disparate compo...
Autores principales: | Tan, Haozhou, Ma, Chunlong, Wang, Jun |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer US
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9095416/ https://www.ncbi.nlm.nih.gov/pubmed/35578732 http://dx.doi.org/10.1007/s00044-022-02903-0 |
Ejemplares similares
-
Invalidation of dieckol and 1,2,3,4,6-pentagalloylglucose (PGG) as SARS-CoV-2 main protease inhibitors and the discovery of PGG as a papain-like protease inhibitor
por: Tan, Haozhou, et al.
Publicado: (2022) -
High Capability of Pentagalloylglucose (PGG) in Inhibiting Multiple Types of Membrane Ionic Currents
por: Chang, Wei-Ting, et al.
Publicado: (2020) -
Validation and Invalidation of SARS-CoV-2 Papain-like
Protease Inhibitors
por: Ma, Chunlong, et al.
Publicado: (2022) -
Validation and invalidation of SARS-CoV-2 main protease inhibitors using the Flip-GFP and Protease-Glo luciferase assays
por: Ma, Chunlong, et al.
Publicado: (2022) -
The inhibitory effects of PGG and EGCG against the SARS-CoV-2 3C-like protease
por: Chiou, Wei-Chung, et al.
Publicado: (2022)